These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

870 related items for PubMed ID: 15824216

  • 1. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC, Visudyne in Minimally Classic Choroidal Neovascularization Study Group.
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [Abstract] [Full Text] [Related]

  • 2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [Abstract] [Full Text] [Related]

  • 3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [Abstract] [Full Text] [Related]

  • 4. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group.
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [Abstract] [Full Text] [Related]

  • 5. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [Abstract] [Full Text] [Related]

  • 6. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
    Verteporfin in Photodynamic Therapy Study Group.
    Ophthalmology; 2001 May; 108(5):841-52. PubMed ID: 11320011
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A, DENALI Study Group.
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [Abstract] [Full Text] [Related]

  • 15. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM.
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group.
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.
    Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH, Sickenberg M, Sternberg P, Aaberg TM, Aaberg TM, Reaves TA, Verteporfin in Ocular Histoplasmosis (VOH) Study Group.
    Ophthalmology; 2002 Aug; 109(8):1499-505. PubMed ID: 12153802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.